Video

Dr. Brahmer on the IMpower150 Trial in NSCLC

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the clinical application of the IMpower150 trial in patients with non–small cell lung cancer (NSCLC).

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the clinical application of the IMpower150 trial in patients with non—small cell lung cancer (NSCLC).

Physicians now have data from the IMpower150 trial in which atezolizumab (Tecentriq) was combined with 3 other drugs—– bevacizumab (Avastin), paclitaxel, and carboplatin. That was compared to chemotherapy plus bevacizumab. Though progression-free survival (PFS) was improved, overall survival was not improved, notes Brahmer. Many physicians are interested in the fact that this was the only trial to include patients with EGFR-mutated disease. Not only were these patients included in the trial, but an improvement in PFS was seen in that subset of patients when atezolizumab was added to the chemotherapy and bevacizumab backbone.

Though provocative, Brahmer says physicians need to see larger studies with that subgroup of patients before combining the 4-drug regimen together in practice.

Related Videos
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School